The Consumer Affairs Agency in Japan authorized the use of 600mg/d of ApplePhenon for people with relatively high BMI for the reduction of abdominal fat.
Photo © iStockphoto.com/hidesy
BGG World (BGG; Tokyo) obtained a “Foods with Functional Claims” health claim for ApplePhenonin Japan. The Consumer Affairs Agency authorized the use of 600mg/d of ApplePhenon for people with relatively high BMI with the following wording:
“This product contains procyanidins derived from apples. The procyanidins from apples are reported to reduce relatively high BMI by supporting the decrease of body weight, body fat, visceral fat, waist circumference, and belly fat (total abdominal fat). This product is suitable for people with relatively high BMI."
“At BGG we previously obtained a claim to market ApplePhenon in Japan for skin whitening,” said Yanmei Li, PhD, global chief scientific officer of BGG, in a press release. “In South Korea, we experienced a huge success with a weight-loss claim, and we hope with this new claim for belly fat (total abdominal fat) to replicate this success, offering our customers another highly appealing claim to support their activities in our top market—Japan.”
ApplePhenon has been clinically validated for weight management, for supporting cardiovascular health, in the management of healthy glucose levels, for skin health and skin liver spots, for dental care, for respiratory support, and in the sports and endurance category.
DOJ asks Utah court to dismiss FTC lawsuit against Xlear Inc.
March 11th 2025On March 10, the DOJ and the defendant filed a stipulation to dismiss with prejudice the lawsuit in which each party agrees “to be responsible for its own costs and fees and agrees that no party shall be responsible to any other party for any fines, costs, fees, or penalties arising from this case.”
HHS announces efforts to eliminate independent conclusion of GRAS
Published: March 11th 2025 | Updated: March 11th 2025U.S. Department of Health and Human Services (HHS) Secretary, Robert F. Kennedy Jr., is directing the acting U.S. Food and Drug Administration’s (FDA) acting commissioner to explore rulemaking that would eliminate the independent conclusion of GRAS provision.